Last 38 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 7.93 | — | — | 1.10 | — | — | — | — | — | — | — | 0.38 | — | — | — | 0.79 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | -51.3% | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.16 | — | 129.88 | 0.87 | 8.68 | 3.44 | 1.70 | 0.92 | 1.35 | 1.72 | 5.47 | 0.27 | 0.63 | 7.02 | 9.20 | 0.45 | 16.58 | 6.82 | 287.12 | 46.87 | 208.88 |
| — | — | +7554.0% | -5.7% | +544.7% | +100.1% | -69.0% | +248.4% | +115.1% | -75.5% | -40.5% | -41.6% | -96.2% | +2.9% | -96.8% | -99.0% | -92.1% | -86.1% | +1836.4% | -32.6% | +1263.6% | |
| P/B Ratio | 1.19 | 2.90 | 2.53 | 2.34 | 3.99 | 4.95 | 1.18 | 1.21 | 1.11 | 0.87 | 0.96 | 0.73 | 1.19 | 1.39 | 1.17 | 1.11 | 2.21 | 0.68 | 4.54 | 5.83 | 5.29 |
| — | -41.4% | +114.8% | +94.2% | +260.7% | +468.0% | +23.3% | +65.2% | -6.8% | -37.4% | -18.6% | -34.2% | -46.2% | +104.6% | -74.1% | -81.0% | -58.2% | -85.2% | +24.6% | +45.0% | +186.8% | |
| P/FCF | — | — | 2.11 | — | 1.52 | — | — | — | 1.42 | — | 3.88 | — | 1.00 | — | — | 0.48 | — | — | — | — | — |
| — | — | — | — | +6.9% | — | — | — | +41.8% | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 3.57 | — | — | 0.79 | — | — | — | — | — | — | — | 0.04 | — | — | — | -0.17 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | +120.6% | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 0.79 | — | — | — | — | — | — | — | 0.04 | -1.80 | — | — | -0.17 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | +121.2% | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | -131.6% | -529.0% | 100.0% | -132.7% | 100.0% | 32.8% | 97.6% | -250.1% | -334.0% | 100.0% | 100.0% | 100.0% | 100.0% | -527.7% | 100.0% |
| — | — | +176.0% | +118.9% | 0.0% | +175.4% | -231.6% | -1714.8% | +2.5% | +47.0% | +129.9% | -67.2% | -2.4% | -350.1% | -434.0% | +118.9% | 0.0% | 0.0% | +165.7% | -627.7% | +129.1% | |
| Operating Margin | -0.0% | — | -2921.7% | 79.2% | -259.7% | -20.7% | -250.8% | -144.4% | -138.0% | -186.9% | -332.6% | 68.7% | -7.6% | -474.6% | -687.6% | 55.9% | -1093.7% | -2910.7% | -12229.6% | -1002.3% | -3181.4% |
| — | — | -1065.0% | +154.8% | -88.1% | +88.9% | +24.6% | -310.1% | -1718.2% | +60.6% | +51.6% | +22.9% | +99.3% | +83.7% | +94.4% | +105.6% | +65.6% | -230.6% | -4501.1% | -1.7% | -568.2% | |
| Net Margin | 14.4% | — | -2791.9% | 79.5% | -242.2% | -14.4% | -236.1% | -138.8% | -127.3% | -175.2% | -301.4% | 69.6% | -12.6% | -438.7% | -641.2% | 57.8% | -1079.0% | -3201.1% | -13291.1% | -1065.6% | -3180.9% |
| — | — | -1082.7% | +157.2% | -90.2% | +91.8% | +21.7% | -299.4% | -911.8% | +60.1% | +53.0% | +20.6% | +98.8% | +86.3% | +95.2% | +105.4% | +66.1% | -263.0% | -4895.4% | -9.3% | -571.1% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.3% | -19.7% | -12.9% | 73.7% | -24.9% | -5.1% | -34.7% | -37.4% | -23.5% | -20.2% | -12.5% | 63.8% | -5.9% | -19.9% | -18.8% | 49.4% | -34.1% | -58.3% | -43.6% | -29.2% | -22.3% |
| — | -285.5% | +62.9% | +297.0% | -6.0% | +74.8% | -178.1% | -158.7% | -297.5% | -1.5% | +33.8% | +29.1% | +82.7% | +65.8% | +56.7% | +269.1% | -53.2% | -228.2% | -181.3% | -108.1% | -21.5% | |
| ROA | 9.6% | -17.1% | -11.3% | 51.2% | -12.7% | -2.4% | -14.7% | -17.0% | -12.0% | -11.2% | -7.2% | 35.4% | -3.1% | -11.3% | -11.2% | 28.3% | -18.2% | -27.4% | -20.7% | -18.5% | -17.0% |
| — | -602.8% | +23.6% | +401.2% | -5.5% | +78.4% | -103.5% | -148.1% | -286.6% | +0.2% | +35.3% | +25.0% | +82.9% | +58.8% | +46.0% | +252.7% | -6.9% | -93.9% | -58.3% | -54.7% | -14.6% | |
| ROIC | -0.2% | — | -54.0% | 1635.7% | — | — | — | — | -177.1% | -69.5% | -37.9% | 4176.2% | — | — | — | — | — | -85.3% | -144.3% | — | -104.3% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -131.7% | -416.2% | — | -7.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.05 | 0.05 | 0.13 | 0.11 | 0.12 | 0.09 | 0.07 | 0.06 | 0.05 | 0.05 | 0.11 | 0.11 | 0.10 | 0.09 | 0.21 | 0.19 | 0.93 | 0.08 | 0.06 |
| — | -58.0% | -60.1% | -47.4% | +79.3% | +79.5% | +114.9% | +79.7% | -35.0% | -45.0% | -44.6% | -40.8% | -48.9% | -42.8% | -89.4% | +5.4% | +228.7% | +136.5% | +1343.6% | +40.0% | +6.9% | |
| Debt / EBITDA | 0.33 | — | — | 0.09 | — | — | — | — | — | — | — | 0.11 | — | — | — | 0.26 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | -57.0% | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.59 | 6.12 | 10.50 | 7.59 | 3.83 | 3.97 | 2.56 | 2.19 | 2.68 | 2.68 | 3.35 | 3.53 | 4.01 | 5.10 | 4.42 | 5.04 | 3.26 | 3.65 | 1.92 | 8.46 | 7.64 |
| — | +54.0% | +309.6% | +247.1% | +43.0% | +48.4% | -23.5% | -38.1% | -33.2% | -47.5% | -24.2% | -29.9% | +23.2% | +39.7% | +130.6% | -40.4% | -57.3% | -56.0% | -73.7% | -12.8% | -6.0% | |
| Quick Ratio | 7.59 | 6.12 | 10.50 | 7.59 | 3.83 | 3.97 | 2.56 | 2.19 | 2.68 | 2.68 | 3.35 | 3.53 | 4.01 | 5.10 | 4.42 | 5.25 | 3.26 | 3.65 | 1.92 | 8.46 | 7.64 |
| — | +54.0% | +309.6% | +247.1% | +43.0% | +48.4% | -23.5% | -38.1% | -33.2% | -47.5% | -24.2% | -32.7% | +23.2% | +39.7% | +130.6% | -38.0% | -57.3% | -56.0% | -73.7% | -12.8% | -6.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -244.15 | -12.19 | -14.18 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 38 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SPRO stock.
Spero Therapeutics, Inc.'s current P/E is 7.9x. The average P/E over the last 1 quarters is 1.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Spero Therapeutics, Inc.'s current operating margin is -0.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Spero Therapeutics, Inc.'s business trajectory between earnings reports.